Literature DB >> 3330458

Sequential determination of IgG subclasses and IgA specific antibodies in primary and reactivating toxoplasmosis.

F Derouin1, G Sulcebe, J J Ballet.   

Abstract

During the course of T. gondii infection, we have analysed serum IgG and IgA antibodies responses in 50 immunocompetent with acquired infection and 19 immunocompromised patients with evidence of reactivated toxoplasmosis. Using an ELISA, IgG1, IgG2, IgG3 and IgA antibodies were found in sera of all patients, whereas IgG4 antibodies were usually not detectable. In immunocompetent patients, the predominant antibody isotype was IgG1 at the different stages of infection, presumably in relation with a T-cell control of humoral response during toxoplasmosis. In immunocompromised hosts (kidney or bone marrow transplanted and HIV infected patients), a sequential study was performed on serum samples taken before and after reactivation had occurred. The isotypic distribution of antibodies was similar to that observed in immunocompetent patients, but differences between groups of immunocompromised patients were detected when the kinetics of the antibody response was considered. The IgG and IgA antibody rise was lower in HIV1 infected patients with clinical toxoplasmosis; whatever was the peak antibody value, clinical symptoms appeared earlier in patients with a slower antibody response. This presumably reveals a functional T-cell abnormality, which may rely to the defective containment of the parasite in these patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3330458

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis.

Authors:  M Paul
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

2.  Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to Toxoplasma gondii.

Authors:  J Hackett; J Hoff-Velk; A Golden; J Brashear; J Robinson; M Rapp; M Klass; D H Ostrow; W Mandecki
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii.

Authors:  B R Dannemann; W C Vaughan; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  Detection of specific immunoglobulin E in patients with toxoplasmosis.

Authors:  J M Pinon; D Toubas; C Marx; G Mougeot; A Bonnin; A Bonhomme; M Villaume; F Foudrinier; H Lepan
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

5.  Toxoplasma antigens recognized by human immunoglobulin A antibodies.

Authors:  J Huskinson; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

6.  Two cases of cerebral toxoplasmosis in AIDS patients mimicking HIV-related dementia.

Authors:  G Arendt; H Hefter; C Figge; E Neuen-Jakob; H W Nelles; C Elsing; H J Freund
Journal:  J Neurol       Date:  1991-12       Impact factor: 4.849

7.  Toxoplasma antigens recognized by immunoglobulin G subclasses during acute and chronic infection.

Authors:  J Huskinson; P N Stepick-Biek; F G Araujo; P Thulliez; Y Suzuki; J S Remington
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

8.  Toxoplasma-SPECIFIC IgG SUBCLASS ANTIBODY RESPONSE IN CEREBROSPINAL FLUID SAMPLES FROM PATIENTS WITH CEREBRAL TOXOPLASMOSIS.

Authors:  Fernanda S Nascimento; Lisandra A Suzuki; Nilson Branco; Regina M B Franco; Paula D Andrade; Sandra C B Costa; Marcelo N Pedro; Cláudio L Rossi
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Sep-Oct       Impact factor: 1.846

9.  Comparative Performance of Recombinant GRA6, GRA7, and GRA14 for the Serodetection of T. gondii Infection and Analysis of IgG Subclasses in Human Sera from the Philippines.

Authors:  Rochelle Haidee Ybañez; Yoshifumi Nishikawa
Journal:  Pathogens       Date:  2022-02-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.